Company intelligence / Profile preview

Poli Pharmaceutics

Owens Cross Roads, AL, USApolypharm.net ↗

Ownership: Private
Employees: ~39
Development stage: Other

Overview

Poly Pharmaceuticals develops, manufactures, markets, and distributes a range of branded, generic, and OTC pharmaceutical products focused on cough/cold, allergy/sinusitis, pain relief, and urological health. The company was acquired by ADDvise Group AB in October 2021. It continues to operate as an active specialty pharma business with commercialized products such as Alahist, Deconex, Duraflu, Poly Hist/Poly Tussin/Poly Vent/Udamin SP.

Therapeutic areas: Men's HealthNeurologyInfectious DiseasesImmunology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

dihydro-alpha-ergocryptine

Unknown

Partnerships

AxisCare Health Logistics Inc. (distribution order)

Beyond the preview

Go deeper on Poli Pharmaceutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poli Pharmaceutics.

Explore the full profile